Showing results (1271-1280 of 1,308) with videos related to

Sort By:
Pageof 131
Gut|February 23, 2025
Multicentre randomised controlled trial of a self-assembling haemostatic gel to prevent delayed bleeding following endoscopic mucosal resection (PURPLE Trial)Jan Drews, Markus Zachäus, Tobias Kleemann, et al.
European Journal of Immunology|August 21, 2007
Extensive HLA class I allele promiscuity among viral CTL epitopesNicole Frahm, Karina Yusim, Todd J Suscovich, et al.
Journal of Virology|February 14, 2004
Consistent cytotoxic-T-lymphocyte targeting of immunodominant regions in human immunodeficiency virus across multiple ethnicitiesNicole Frahm, B T Korber, C M Adams, et al.
Annals of Internal Medicine|February 3, 2016
Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention: A Randomized TrialLindsey R Baden, Etienne Karita, Gaudensia Mutua, et al.
Human Gene Therapy|March 17, 2023
Assessment of Pre-Clinical Liver Models Based on Their Ability to Predict the Liver-Tropism of Adeno-Associated Virus VectorsAdrian Westhaus, Marti Cabanes-Creus, Kimberley L Dilworth, et al.
JAMA|April 20, 2016
Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical TrialIain D Milligan, Malick M Gibani, Richard Sewell, et al.
The Journal of Infectious Diseases|October 18, 2015
Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083Stephen R Walsh, Zoe Moodie, Andrew J Fiore-Gartland, et al.
Plos One|January 31, 2020
Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South AfricansLue Ping Zhao, Andrew Fiore-Gartland, Lindsay N Carpp, et al.
Open Forum Infectious Diseases|July 23, 2015
First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Vesicular Stomatitis Virus Human Immunodeficiency Virus-1 gag Vaccine (HVTN 090)Jonathan D Fuchs, Ian Frank, Marnie L Elizaga, et al.
Plos Medicine|February 25, 2020
Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccinesFatima Laher, Zoe Moodie, Kristen W Cohen, et al.
Pageof 131